Phase 3 study on previously untreated chronic lymphocytic leukemia showed sustained PFS with venetoclax-obinutuzumab.
Medscape Medical News, June 30, 2023 EHA 2023 CLL: Venetoclax-Obinutuzumab Combo Effective Long Term Patients with chronic lymphocytic leukemia (CLL) experience long-term progression-free survival ...
Medpage Today on MSN2mon
Chemo-Free Triplet Yields 68% Response Rate in Richter TransformationAmong 28 previously untreated patients, the overall response rate reached 67.9% (95% CI 47.6-84.1) following six cycles of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback